Drug Profile
Amcasertib - Sumitomo Pharma America
Alternative Names: BB503; BBI 503; GB-503Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boston Biomedical
- Developer Boston Biomedical; Sumitomo Pharma
- Class Antineoplastics; Indoles; Pyrroles; Small molecules; Thiazoles
- Mechanism of Action Cell death stimulants; Phosphotransferase inhibitors; Protein-serine-threonine kinase inhibitors; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cholangiocarcinoma; Gastrointestinal stromal tumours; Liver cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 01 Apr 2022 Sumitomo Dainippon Pharma Oncology is now called Sumitomo Pharma Oncology
- 01 Dec 2020 Boston Biomedical completes a phase II trial for liver cancer and Cholangiocarcinoma (Late-stage disease, Second-line or greater, Metastatic disease, Unresectable/Inoperable) Canada (NCT02232633)